Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive ...
After being told he might not walk for two years, the longtime Little League football coach fought through treatment to ...
I think it's great to see others recognizing the importance of Graves' as a disease. It's great to see more people working on ...
Antonio Urbina, MD, the medical director for the Mount Sinai Institute for Advanced Medicine 7th Avenue clinic in New York ...
Real-world data on usage of the tyrosine kinase inhibitor nintedanib (Ofev; Boehringer Ingelheim) suggest there is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback